Prescribing and borderline personality disorder

Australian Prescriber

Volumn 39, Issue 2, 2016, Pages 49-53

  Chanen, Andrew M ^a,b,c   Thompson, Katherine N ^a,b  

^a Orygen: The National Centre of Excellence in Youth Mental Health   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c NorthWestern Mental Health   (Australia)

Author keywords

Anti psychotic agent; Antidepressant; Borderline personality disorder; Polypharmacy; Psychosocial intervention strategy

Indexed keywords

ARIPIPRAZOLE; LAMOTRIGINE; MOOD STABILIZER; OLANZAPINE; OMEGA 3 FATTY ACID; PSYCHOTROPIC AGENT; QUETIAPINE; TOPIRAMATE; VALPROIC ACID;

ARTICLE; BEHAVIOR THERAPY; BORDERLINE STATE; CLINICAL FEATURE; COGNITIVE THERAPY; COMORBIDITY; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DSM-5; EVIDENCE BASED MEDICINE; HUMAN; HUMAN RELATION; IMPULSIVENESS; MEDICAL SOCIETY; MOOD DISORDER; PARANOIA; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHOLOGICAL AND PSYCHIATRIC PROCEDURES; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF CONCEPT; SUICIDE;

EID: 84962477144     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2016.019     Document Type: Article

References (32)

1. Chanen AM, McCutcheon L. Prevention and early intervention for borderline personality disorder: current status and recent evidence. Br J Psychiatry Suppl 2013;202:s24-9. http://dx.doi.org/10.1192/bjp.bp.112.119180
2. Lenzenweger MF. Epidemiology of personality disorders [vi.]. Psychiatr Clin North Am 2008;31:395-403. http://dx.doi.org/10.1016/j.psc.2008.03.003
3. Trull TJ, Jahng S, Tomko RL, Wood PK, Sher KJ. Revised NESARC personality disorder diagnoses: gender, prevalence, and comorbidity with substance dependence disorders. J Pers Disord 2010;24:412-26. http://dx.doi.org/10.1521/pedi.2010.24.4.412
4. Torgersen S, Kringlen E, Cramer V. The prevalence of personality disorders in a community sample. Arch Gen Psychiatry 2001;58:590-6. http://dx.doi.org/10.1001/archpsyc.58.6.590
5. Gross R, Olfson M, Gameroff M, Shea S, Feder A, Fuentes M, et al. Borderline personality disorder in primary care. Arch Intern Med 2002;162:53-60. http://dx.doi.org/10.1001/archinte.162.1.53
6. Riihimäki K, Vuorilehto M, Isometsä E. Borderline personality disorder among primary care depressive patients: a five-year study. J Affect Disord 2014;155:303-6. http://dx.doi.org/10.1016/j.jad.2013.10.050
7. Zimmerman M, Chelminski I, Young D. The frequency of personality disorders in psychiatric patients [vi.]. Psychiatr Clin North Am 2008;31:405-20. http://dx.doi.org/10.1016/j.psc.2008.03.015
8. Chanen AM, Jovev M, Djaja D, McDougall E, Yuen HP, Rawlings D, et al. Screening for borderline personality disorder in outpatient youth. J Pers Disord 2008;22:353-64. http://dx.doi.org/10.1521/pedi.2008.22.4.353
9. Gunderson JG, Stout RL, McGlashan TH, Shea MT, Morey LC, Grilo CM, et al. Ten-year course of borderline personality disorder: psychopathology and function from the Collaborative Longitudinal Personality Disorders study. Arch Gen Psychiatry 2011;68:827-37. http://dx.doi.org/10.1001/archgenpsychiatry.2011.37
10. Hoffman PD, Buteau E, Hooley JM, Fruzzetti AE, Bruce ML. Family members’ knowledge about borderline personality disorder: correspondence with their levels of depression, burden, distress, and expressed emotion. Fam Process 2003;42:469-78. http://dx.doi.org/10.1111/j.1545-5300.2003.00469.x
11. El-Gabalawy R, Katz LY, Sareen J. Comorbidity and associated severity of borderline personality disorder and physical health conditions in a nationally representative sample. Psychosom Med 2010;72:641-7. http://dx.doi.org/10.1097/PSY.0b013e3181e10c7b
12. Fok ML, Hayes RD, Chang CK, Stewart R, Callard FJ, Moran P. Life expectancy at birth and all-cause mortality among people with personality disorder. J Psychosom Res 2012;73:104-7. http://dx.doi.org/10.1016/j.jpsychores.2012.05.001
13. Pompili M, Girardi P, Ruberto A, Tatarelli R. Suicide in borderline personality disorder: a meta-analysis. Nord J Psychiatry 2005;59:319-24. http://dx.doi.org/10.1080/08039480500320025
14. Hörz S, Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G. Ten-year use of mental health services by patients with borderline personality disorder and with other axis II disorders. Psychiatr Serv 2010;61:612-6. http://dx.doi.org/10.1176/ps.2010.61.6.612
15. Andrews G, Titov N. Changing the face of mental health care through needs-based planning. Aust Health Rev 2007;31 Suppl 1:S122-8. http://dx.doi.org/10.1071/AH07S122
16. National Health and Medical Research Council. Clinical Practice Guideline for the Management of Borderline Personality Disorder. Melbourne: National Health and Medical Research Council; 2012.
17. Leichsenring F, Leibing E, Kruse J, New AS, Leweke F. Borderline personality disorder. Lancet 2011;377:74-84. http://dx.doi.org/10.1016/S0140-6736(10)61422-5
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): American Psychiatric Association; 2013.
19. Zimmerman M, Chelminski I, Young D, Dalrymple K, Martinez J. Does the presence of one feature of borderline personality disorder have clinical significance? Implications for dimensional ratings of personality disorders. J Clin Psychiatry 2012;73:8-12. http://dx.doi.org/10.4088/JCP.10m06784
20. Tyrer P, Reed GM, Crawford MJ. Classification, assessment, prevalence, and effect of personality disorder. Lancet 2015;385:717-26. http://dx.doi.org/10.1016/S0140-6736(14)61995-4
21. Chanen AM. Borderline personality disorder in young people: are we there yet? J Clin Psychol 2015;71:778-91. http://dx.doi.org/10.1002/jclp.22205
22. Crawford TN, Cohen P, First MB, Skodol AE, Johnson JG, Kasen S. Comorbid Axis I and Axis II disorders in early adolescence: outcomes 20 years later. Arch Gen Psychiatry 2008;65:641-8. http://dx.doi.org/10.1001/archpsyc.65.6.641
23. Cohen P, Crawford TN, Johnson JG, Kasen S. The children in the community study of developmental course of personality disorder. J Pers Disord 2005;19:466-86. http://dx.doi.org/10.1521/pedi.2005.19.5.466
24. Stoffers JM, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev 2012;8:CD005652.
25. Bateman AW, Gunderson J, Mulder R. Treatment of personality disorder. Lancet 2015;385:735-43. http://dx.doi.org/10.1016/S0140-6736(14)61394-5
26. De Panfilis C, Marchesi C, Cabrino C, Monici A, Politi V, Rossi M, et al. Patient factors predicting early dropout from psychiatric outpatient care for borderline personality disorder. Psychiatry Res 2012;200:422-9. http://dx.doi.org/10.1016/j.psychres.2012.03.016
27. Stoffers J, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev 2010;6:CD005653.
28. National Collaborating Centre for Mental Health. Borderline personality disorder: treatment and management. Report No.: CG78. London: National Institute for Health and Clinical Excellence; 2009.
29. Stoffers JM, Lieb K. Pharmacotherapy for borderline personality disorder-- current evidence and recent trends. Curr Psychiatry Rep 2015;17:534. http://dx.doi.org/10.1007/s11920-014-0534-0
30. Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry 2010;196:4-12. http://dx.doi.org/10.1192/bjp.bp.108.062984
31. Tyrer P, Silk KR. A comparison of UK and US guidelines for drug treatment in borderline personality disorder. Int Rev Psychiatry 2011;23:388-94. http://dx.doi.org/10.3109/09540261.2011.606540
32. Zanarini MC, Frankenburg FR, Hennen J, Silk KR. Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. J Clin Psychiatry 2004;65:28-36. http://dx.doi.org/10.4088/JCP.v65n0105